Here are three things to know.
- Nevisense is intended to help clinicians detect early stages of malignant melanoma.
- Clinicians may use the device to further assess suspicious skin lesions with one or more characteristics of melanoma before conducting a biopsy.
- The device, which uses electrical signals to measure and assess the skin, should not be used to confirm a clinical melanoma diagnosis.
More articles on supply chain:
UPS to freeze 70k workers’ pensions: 3 things to know
Philips to acquire Spectranetics devicemaker for $2.2B: 5 things to know
Valeant ‘most exposed’ to generic competition by FDA’s new drug list, says analyst
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
